Functional Constipation and the Gut Microbiome in Children: Preclinical and Clinical Evidence

David Avelar Rodriguez1,2, Jelena Popov3, Elyanne M Ratcliffe4

  • 1Department of Pediatric Gastroenterology and Nutrition, Instituto Nacional de Pediatría, Mexico City, Mexico.

Frontiers in Pediatrics
|February 8, 2021
PubMed

Insights

Pediatric functional constipation, often resistant to treatment, may be influenced by the gut microbiome. This review explores how gut bacteria could contribute to constipation symptoms in children.

Area of Science:

  • Pediatric Gastroenterology
  • Microbiome Research
  • Child Health

Background:

  • Functional constipation is a prevalent childhood condition impacting quality of life and healthcare costs.
  • Symptoms include infrequent bowel movements and hard stools, causing distress for children and families.
  • A significant percentage of children experience persistent constipation into adulthood, indicating unmet treatment needs.

Purpose of the Study:

  • To review preclinical and clinical evidence on the gut microbiome's role in pediatric functional constipation.
  • To explore potential mechanisms linking gut microbiota to constipation pathophysiology in children.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of clinical research investigating the gut microbiome in pediatric functional constipation.

Main Results:

  • The gut microbiome is increasingly recognized as a potential factor in functional constipation.
  • Evidence suggests specific microbial compositions or functions may contribute to symptom development.
  • Further research is needed to fully elucidate these complex interactions.

Conclusions:

  • The gut microbiome represents a promising area for understanding and potentially treating pediatric functional constipation.
  • Targeting the gut microbiota could offer novel therapeutic strategies for refractory cases.
  • This review highlights the importance of considering the microbiome in pediatric constipation management.

Related Concept Videos

Anatomy of the Intestines01:23

Anatomy of the Intestines

Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
85.5K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
468
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
634
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
477
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
806
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
653